focus -WSS

focus

author：entertainment 2025-09-28 00:50:20 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： As Taiwan prepares for anti

WSS

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Elizabeth Warren probes abortion access

Cholera vaccine supply gets boost as demand surges globally

More tobacco lobbyists active in statehouses

Cue Health's Covid

In new study, freeze

knowledge

focus

explore

New air purifier tech could be key to improving indoor air quality

Orangutan used medicinal plant to treat wound, first time ever seen

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

7 of the most gruesome medical devices in history

How one medical school became remarkably diverse

Key Senate committee drafts bipartisan bill to stem drug shortages

Bright Health sells Medicare Advantage business to Molina

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC backtracks, saying fully vaccinated people can go maskless indoors

focus

Medical bills so high, Medicare adding extra digits to claim forms

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Getting Alzheimer's drug Leqembi to patients can be a challenge

Melinda French Gates resigns from Gates Foundation

H5N1 bird flu found in pasteurized milk: what we know

As Taiwan prepares for anti

entertainment

focus

knowledge

explore